Exagen(US:XGN) Globenewswire·2025-10-23 13:15Core Insights - Exagen Inc. announced the acceptance of six abstracts at the 2025 American College of Rheumatology's annual meeting, highlighting advancements in autoimmune testing [1][2][3] Group 1: Research and Presentations - A plenary presentation in collaboration with Johns Hopkins University will focus on a urinary biomarker panel for guiding precision management of Lupus Nephritis [2][3] - Additional abstracts will cover innovative research on anti-RA33, anti-PAD4, and traditional biomarkers to improve rheumatoid arthritis diagnostic accuracy, as well as T Cell biomarkers to differentiate systemic lupus erythematosus from other conditions [2][3] - Exagen will present preliminary data on a novel kidney damage biomarker panel aimed at transforming early kidney disease management [3] Group 2: Abstract Details - The accepted abstracts include a plenary talk on "Urinary Tenascin C Predicts Kidney Function Loss in Lupus Nephritis" scheduled for October 27, 2025 [4] - Other presentations will feature a machine learning classifier for rheumatoid arthritis and a kidney-specific biomarker panel that differentiates Lupus Nephritis from diabetic kidney disease [4][5] - A poster presentation will discuss the clinical utility of a multianalyte lupus risk score incorporating cell-bound complement activation products [6] Group 3: Company Overview - Exagen Inc. is a leading provider of autoimmune diagnostics, focused on improving patient care for chronic autoimmune conditions [7] - The company's flagship product, AVISE CTD, enhances the diagnosis of complex autoimmune diseases such as lupus and rheumatoid arthritis [7] - Exagen operates a CLIA-certified, CAP-accredited laboratory specializing in rheumatic disease testing, emphasizing research, innovation, and patient-centered care [7]